Join
Live feed
·
PRReleasevia Quantisnow
ACADIA Pharmaceuticals Inc. logo

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

ByQuantisnow·Wall Street's wire, on your screen.
ACAD· ACADIA Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACAD (ACADIA Pharmaceuticals Inc.) and more on Quantisnow.